2001
DOI: 10.1016/s0168-8278(01)00130-1
|View full text |Cite
|
Sign up to set email alerts
|

Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

29
3,116
4
106

Year Published

2007
2007
2012
2012

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 3,918 publications
(3,255 citation statements)
references
References 118 publications
29
3,116
4
106
Order By: Relevance
“…57 With respect to the current EASL and AASLD guidelines, it is obviously important to know the diagnostic accuracy of noninvasive criteria for small nodules. [1][2][3] Analyzing the 4 level 1b studies, we were able to extract data about the diagnostic accuracy with respect to the size from 2 studies 32,57 ; the study by Forner et al 56 was specifically designed to address this question (Table 8). Lesions 10 mm were rather infrequently HCC (14.6%), and the diagnostic sensitivity decreased with the size from 100% (for CT and MRI) for lesions > 20 mm to 10% to 50% (for CT) or 34% to 70% (for MRI) for lesions < 10 mm 32 or 10 mm.…”
Section: Level 1b Studiesmentioning
confidence: 99%
See 1 more Smart Citation
“…57 With respect to the current EASL and AASLD guidelines, it is obviously important to know the diagnostic accuracy of noninvasive criteria for small nodules. [1][2][3] Analyzing the 4 level 1b studies, we were able to extract data about the diagnostic accuracy with respect to the size from 2 studies 32,57 ; the study by Forner et al 56 was specifically designed to address this question (Table 8). Lesions 10 mm were rather infrequently HCC (14.6%), and the diagnostic sensitivity decreased with the size from 100% (for CT and MRI) for lesions > 20 mm to 10% to 50% (for CT) or 34% to 70% (for MRI) for lesions < 10 mm 32 or 10 mm.…”
Section: Level 1b Studiesmentioning
confidence: 99%
“…These guidelines have been validated in 3 studies 56,58,59 (Tables 9 and 10). The prospective study by Leoni et al 58 used the EASL guidelines 3 to establish the diagnosis of HCC for 75 consecutive small lesions (10-30 mm) detected by ultrasonography. In addition, the old AASLD guidelines 1 were analyzed (but only retrospectively).…”
Section: Question 4 Are There Studies Validating the Current Guidelimentioning
confidence: 99%
“…A European Association for the Study of the Liver panel of experts recommended the consideration of 4 related aspects: the tumor stage, the degree of functional impairment, the general condition of the patient, and the treatment efficacy. 21 It is clear that patients with early-stage HCC (whatever definition is used) will be considered for treatment by resection, liver transplantation, or ablation, and their survival is expected to be relatively good; for patients whose disease is terminal and malignant [severe symptoms, liver impairment (ChildPugh class C with no chance for liver transplantation), or huge tumors], the survival time will be very short. In patients with untreated, non-early-stage, nonterminal HCC, 3 independent predictive factors have been identified for a poor prognosis: constitutional and cancer-related symptoms (according to the Eastern Cooperative Oncology Group performance status), vascular invasion, and extrahepatic spread.…”
Section: Formentioning
confidence: 99%
“…[22][23][24][25] In addition to these prospective validations, several studies have demonstrated the ability of the model. 26,27 It has been recently endorsed by numerous groups 1,21,28 and is included in the guidelines for the management of HCC from the American Association for the Study of Liver Diseases. 29 Other staging systems such as the CLIP system have also been externally validated.…”
Section: Formentioning
confidence: 99%
“…The patient dose not require a biopsy to confirm the diagnosis given the clinical scenario of a hypervascular tumor in the setting of cirrhosis and an elevated AFP. 34 The patient is beyond transplant criteria given evidence of portal vein invasion. However, even without the portal vein thrombus, the patient's tumor volume precludes transplant size criteria.…”
Section: Recommendationsmentioning
confidence: 99%